Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AHB-121
- Development stage
- Phase 1
- Lead developer
- AusperBio
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
AHB-121 is an investigational small molecule therapeutic candidate being developed by AusperBio (Hangzhou Haobo Pharmaceutical) for the treatment of chronic hepatitis B (CHB). It is administered via subcutaneous injection. In August 2026, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) accepted the Investigational New Drug (IND) application for AHB-121. An ongoing Phase I clinical trial (CTR20263899) is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and cytokine effects of subcutaneous AHB-121 in healthy volunteers and participants with chronic hepatitis B.
Beyond the preview
Go deeper on AHB-121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AHB-121.